Nurix Discontinued Clinical Development of Zelebrudomide
The company halted the BTK degrader program to prioritize its partnered oncology assets.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when deciding which drugs to develop?
Nurix has officially ended the clinical development of its BTK degrader, zelebrudomide, following a review of clinical data. While the program reached the completion of a phase 1 study, the company opted to stop further investment to focus on its remaining oncology portfolio.
Why it matters
The move reflects a strategic consolidation of resources toward Nurix's most promising clinical partnerships. By narrowing its focus, the company aims to accelerate the development of its broader pipeline of targeted protein degraders.
The zelebrudomide program underwent a phase 1 trial, including a clinical hold by the FDA in November 2023 that was subsequently lifted in March 2024. Despite completing enrollment, Nurix decided to pivot away from the degrader to emphasize other candidates.
The players
Nurix
A California-based biotechnology firm focused on the discovery and development of small-molecule drugs that modulate protein degradation.
Roche
A multinational healthcare conglomerate that maintains an extensive oncology portfolio and global clinical development infrastructure.
The details
Zelebrudomide belongs to a class of drugs called BTK degraders, which utilize a small-molecule approach to induce the degradation of Bruton tyrosine kinase, a protein that fuels the growth of certain B-cell cancers. Unlike traditional BTK inhibitors that occupy a binding site on the target protein, degraders hijack the cell's internal machinery to destroy the protein itself. This process is intended to provide greater therapeutic efficacy by removing the protein entirely rather than merely blocking its activity.
Timeline
November 2023: The FDA placed a clinical hold on the zelebrudomide study.
March 2024: The FDA clinical hold on the zelebrudomide study was lifted.
June 2026: Roche paid an upfront fee of $700 million for the rights to bexobrutideg.
July 2026: Nurix completed a review of clinical data for zelebrudomide.
October 12, 2026: Nurix formally announced the discontinuation of zelebrudomide.
The Tech Race
The transition from traditional BTK inhibitors to degraders represents a major shift in cancer research. Nurix is now concentrating its efforts on the development of bexobrutideg, positioning the molecule against established kinase inhibitor standards.
Patients currently enrolled in the zelebrudomide trial may continue their treatment if their healthcare providers determine it remains clinically appropriate. The decision has no immediate impact on commercial drug availability for patients, as the program was in the clinical research phase.
The takeaway
Nurix's exit from the zelebrudomide program highlights the high-stakes trade-offs companies make to secure and fund their most promising lead assets. Investors should monitor the phase 3 progression of bexobrutideg as the key performance indicator for the company's refined oncology strategy.
Further reading
For broader trends in drug development, see the latest coverage in Biotech.
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when deciding which drugs to develop?
